ID   TPH2_HUMAN              Reviewed;         490 AA.
AC   Q8IWU9; A6NGA4; Q14CB0;
DT   09-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   15-MAR-2017, entry version 136.
DE   RecName: Full=Tryptophan 5-hydroxylase 2;
DE            EC=1.14.16.4;
DE   AltName: Full=Neuronal tryptophan hydroxylase;
DE   AltName: Full=Tryptophan 5-monooxygenase 2;
GN   Name=TPH2; Synonyms=NTPH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=12511643; DOI=10.1126/science.1078197;
RA   Walther D.J., Peter J.-U., Bashammakh S., Hortnagl H., Voits M.,
RA   Fink H., Bader M.;
RT   "Synthesis of serotonin by a second tryptophan hydroxylase isoform.";
RL   Science 299:76-76(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   BIOPHYSICOCHEMICAL PROPERTIES, VARIANT SER-206, AND CHARACTERIZATION
RP   OF VARIANTS SER-206 AND HIS-441.
RX   PubMed=17905754; DOI=10.1093/hmg/ddm286;
RA   Cichon S., Winge I., Mattheisen M., Georgi A., Karpushova A.,
RA   Freudenberg J., Freudenberg-Hua Y., Babadjanova G.,
RA   Van Den Bogaert A., Abramova L.I., Kapiletti S., Knappskog P.M.,
RA   McKinney J., Maier W., Jamra R.A., Schulze T.G., Schumacher J.,
RA   Propping P., Rietschel M., Haavik J., Noethen M.M.;
RT   "Brain-specific tryptophan hydroxylase 2 (TPH2): a functional
RT   Pro206Ser substitution and variation in the 5'-region are associated
RT   with bipolar affective disorder.";
RL   Hum. Mol. Genet. 17:87-97(2008).
RN   [5]
RP   ALTERNATIVE SPLICING (ISOFORMS A AND B), AND RNA EDITING OF POSITIONS
RP   433; 441 AND 468.
RC   TISSUE=Brain;
RX   PubMed=20126463; DOI=10.1371/journal.pone.0008956;
RA   Grohmann M., Hammer P., Walther M., Paulmann N., Buttner A.,
RA   Eisenmenger W., Baghai T.C., Schule C., Rupprecht R., Bader M.,
RA   Bondy B., Zill P., Priller J., Walther D.J.;
RT   "Alternative splicing and extensive RNA editing of human TPH2
RT   transcripts.";
RL   PLoS ONE 5:E8956-E8956(2010).
RN   [6]
RP   INVOLVEMENT IN MDD, VARIANT HIS-441, AND CHARACTERIZATION OF VARIANT
RP   HIS-441.
RX   PubMed=15629698; DOI=10.1016/j.neuron.2004.12.014;
RA   Zhang X., Gainetdinov R.R., Beaulieu J.-M., Sotnikova T.D.,
RA   Burch L.H., Williams R.B., Schwartz D.A., Krishnan K.R.R., Caron M.G.;
RT   "Loss-of-function mutation in tryptophan hydroxylase-2 identified in
RT   unipolar major depression.";
RL   Neuron 45:11-16(2005).
RN   [7]
RP   VARIANT ADHD7 TRP-303.
RX   PubMed=18347598; DOI=10.1038/sj.mp.4002152;
RA   McKinney J., Johansson S., Halmoy A., Dramsdahl M., Winge I.,
RA   Knappskog P.M., Haavik J.;
RT   "A loss-of-function mutation in tryptophan hydroxylase 2 segregating
RT   with attention-deficit/hyperactivity disorder.";
RL   Mol. Psychiatry 13:365-367(2008).
RN   [8]
RP   CHARACTERIZATION OF VARIANTS VAL-36; PRO-36; TYR-41; CYS-55; SER-206;
RP   TRP-303; VAL-328; HIS-441 AND GLU-479.
RX   PubMed=19319927; DOI=10.1002/humu.20956;
RA   McKinney J.A., Turel B., Winge I., Knappskog P.M., Haavik J.;
RT   "Functional properties of missense variants of human tryptophan
RT   hydroxylase 2.";
RL   Hum. Mutat. 30:787-794(2009).
CC   -!- CATALYTIC ACTIVITY: L-tryptophan + tetrahydrobiopterin + O(2) = 5-
CC       hydroxy-L-tryptophan + 4a-hydroxytetrahydrobiopterin.
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033; Evidence={ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=41.3 uM for L-tryptophan {ECO:0000269|PubMed:17905754};
CC         Vmax=833 nmol/min/mg enzyme {ECO:0000269|PubMed:17905754};
CC   -!- PATHWAY: Aromatic compound metabolism; serotonin biosynthesis;
CC       serotonin from L-tryptophan: step 1/2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=a;
CC         IsoId=Q8IWU9-1; Sequence=Displayed;
CC       Name=b;
CC         IsoId=Q8IWU9-2; Sequence=VSP_040971;
CC   -!- TISSUE SPECIFICITY: Brain specific.
CC   -!- RNA EDITING: Modified_positions=433 {ECO:0000269|PubMed:20126463},
CC       441 {ECO:0000269|PubMed:20126463}, 468
CC       {ECO:0000269|PubMed:20126463}; Note=Modulates the kinetic
CC       properties of both isoforms.;
CC   -!- DISEASE: Major depressive disorder (MDD) [MIM:608516]: A common
CC       psychiatric disorder. It is a complex trait characterized by one
CC       or more major depressive episodes without a history of manic,
CC       mixed, or hypomanic episodes. A major depressive episode is
CC       characterized by at least 2 weeks during which there is a new
CC       onset or clear worsening of either depressed mood or loss of
CC       interest or pleasure in nearly all activities. Four additional
CC       symptoms must also be present including changes in appetite,
CC       weight, sleep, and psychomotor activity; decreased energy;
CC       feelings of worthlessness or guilt; difficulty thinking,
CC       concentrating, or making decisions; or recurrent thoughts of death
CC       or suicidal ideation, plans, or attempts. The episode must be
CC       accompanied by distress or impairment in social, occupational, or
CC       other important areas of functioning.
CC       {ECO:0000269|PubMed:15629698}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Attention deficit-hyperactivity disorder 7 (ADHD7)
CC       [MIM:613003]: A neurobehavioral developmental disorder primarily
CC       characterized by the coexistence of attentional problems and
CC       hyperactivity, with each behavior occurring infrequently alone.
CC       {ECO:0000269|PubMed:18347598}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry. Naturally occurring variants of TPH2 with impaired enzyme
CC       activity could cause deficiency of serotonin production and result
CC       in an increased risk of developing behavioral disorders.
CC   -!- SIMILARITY: Belongs to the biopterin-dependent aromatic amino acid
CC       hydroxylase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY098914; AAM28946.1; -; mRNA.
DR   EMBL; AC090109; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC114499; AAI14500.1; -; mRNA.
DR   CCDS; CCDS31859.1; -. [Q8IWU9-1]
DR   RefSeq; NP_775489.2; NM_173353.3. [Q8IWU9-1]
DR   UniGene; Hs.736576; -.
DR   PDB; 4V06; X-ray; 2.63 A; A/B=148-490.
DR   PDBsum; 4V06; -.
DR   ProteinModelPortal; Q8IWU9; -.
DR   SMR; Q8IWU9; -.
DR   BioGrid; 125720; 2.
DR   IntAct; Q8IWU9; 1.
DR   MINT; MINT-7997360; -.
DR   STRING; 9606.ENSP00000329093; -.
DR   BindingDB; Q8IWU9; -.
DR   ChEMBL; CHEMBL5433; -.
DR   DrugBank; DB00150; L-Tryptophan.
DR   iPTMnet; Q8IWU9; -.
DR   PhosphoSitePlus; Q8IWU9; -.
DR   BioMuta; TPH2; -.
DR   DMDM; 30580625; -.
DR   PaxDb; Q8IWU9; -.
DR   PeptideAtlas; Q8IWU9; -.
DR   PRIDE; Q8IWU9; -.
DR   Ensembl; ENST00000333850; ENSP00000329093; ENSG00000139287. [Q8IWU9-1]
DR   GeneID; 121278; -.
DR   KEGG; hsa:121278; -.
DR   UCSC; uc009zrw.1; human. [Q8IWU9-1]
DR   CTD; 121278; -.
DR   DisGeNET; 121278; -.
DR   GeneCards; TPH2; -.
DR   HGNC; HGNC:20692; TPH2.
DR   HPA; CAB078198; -.
DR   MalaCards; TPH2; -.
DR   MIM; 607478; gene.
DR   MIM; 608516; phenotype.
DR   MIM; 613003; phenotype.
DR   neXtProt; NX_Q8IWU9; -.
DR   OpenTargets; ENSG00000139287; -.
DR   PharmGKB; PA128747823; -.
DR   eggNOG; KOG3820; Eukaryota.
DR   eggNOG; COG3186; LUCA.
DR   GeneTree; ENSGT00390000010268; -.
DR   HOGENOM; HOG000233373; -.
DR   HOVERGEN; HBG006841; -.
DR   InParanoid; Q8IWU9; -.
DR   KO; K00502; -.
DR   OMA; KNDDKGN; -.
DR   OrthoDB; EOG091G05MZ; -.
DR   PhylomeDB; Q8IWU9; -.
DR   TreeFam; TF313327; -.
DR   BioCyc; MetaCyc:HS06603-MONOMER; -.
DR   BRENDA; 1.14.16.4; 2681.
DR   Reactome; R-HSA-209931; Serotonin and melatonin biosynthesis.
DR   SABIO-RK; Q8IWU9; -.
DR   SIGNOR; Q8IWU9; -.
DR   UniPathway; UPA00846; UER00799.
DR   GeneWiki; TPH2; -.
DR   GenomeRNAi; 121278; -.
DR   PRO; PR:Q8IWU9; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000139287; -.
DR   CleanEx; HS_TPH2; -.
DR   Genevisible; Q8IWU9; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0016597; F:amino acid binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004510; F:tryptophan 5-monooxygenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0009072; P:aromatic amino acid family metabolic process; IEA:InterPro.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0046219; P:indolalkylamine biosynthetic process; TAS:Reactome.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0042427; P:serotonin biosynthetic process; IEA:UniProtKB-UniPathway.
DR   Gene3D; 1.10.800.10; -; 1.
DR   InterPro; IPR002912; ACT_dom.
DR   InterPro; IPR001273; ArAA_hydroxylase.
DR   InterPro; IPR018301; ArAA_hydroxylase_Fe/CU_BS.
DR   InterPro; IPR019774; Aromatic-AA_hydroxylase_C.
DR   InterPro; IPR005963; Trp_5_mOase.
DR   InterPro; IPR019773; Tyrosine_3-monooxygenase-like.
DR   PANTHER; PTHR11473; PTHR11473; 1.
DR   Pfam; PF00351; Biopterin_H; 1.
DR   PIRSF; PIRSF000336; TH; 1.
DR   PRINTS; PR00372; FYWHYDRXLASE.
DR   SUPFAM; SSF56534; SSF56534; 1.
DR   TIGRFAMs; TIGR01270; Trp_5_monoox; 1.
DR   PROSITE; PS51671; ACT; 1.
DR   PROSITE; PS00367; BH4_AAA_HYDROXYL_1; 1.
DR   PROSITE; PS51410; BH4_AAA_HYDROXYL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Iron; Metal-binding; Monooxygenase; Oxidoreductase;
KW   Phosphoprotein; Polymorphism; Reference proteome; RNA editing;
KW   Serotonin biosynthesis.
FT   CHAIN         1    490       Tryptophan 5-hydroxylase 2.
FT                                /FTId=PRO_0000205574.
FT   DOMAIN       65    140       ACT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01007}.
FT   METAL       318    318       Iron. {ECO:0000250}.
FT   METAL       323    323       Iron. {ECO:0000250}.
FT   METAL       363    363       Iron. {ECO:0000250}.
FT   MOD_RES      19     19       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8CGU9}.
FT   VAR_SEQ     147    147       E -> GKE (in isoform b). {ECO:0000305}.
FT                                /FTId=VSP_040971.
FT   VARIANT      36     36       L -> P (the property of the variant is
FT                                indistinguishable from the wild-type;
FT                                dbSNP:rs199775778).
FT                                {ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058938.
FT   VARIANT      36     36       L -> V (the property of the variant is
FT                                indistinguishable from the wild-type;
FT                                dbSNP:rs34115267).
FT                                {ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058939.
FT   VARIANT      41     41       S -> Y (the property of the variant is
FT                                indistinguishable from the wild-type;
FT                                dbSNP:rs78162420).
FT                                {ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058940.
FT   VARIANT      55     55       R -> C (the property of the variant is
FT                                indistinguishable from the wild-type;
FT                                dbSNP:rs75558144).
FT                                {ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058941.
FT   VARIANT     206    206       P -> S (may be associated with
FT                                susceptibility to bipolar affective
FT                                disorder; decreases solubility; decreases
FT                                thermal stability; catalytic activity as
FT                                the wild type; moderate loss-of-function
FT                                observed manifested via stability and
FT                                solubility effect; dbSNP:rs17110563).
FT                                {ECO:0000269|PubMed:17905754,
FT                                ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_046136.
FT   VARIANT     303    303       R -> W (in ADHD7; has severely reduced
FT                                solubility; is completely inactive; loss
FT                                of function may lead to a reduced
FT                                serotonin synthesis; dbSNP:rs120074176).
FT                                {ECO:0000269|PubMed:18347598,
FT                                ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058942.
FT   VARIANT     328    328       A -> V (moderate loss-of-function
FT                                observed manifested via stability and
FT                                solubility effect; dbSNP:rs2887147).
FT                                {ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058943.
FT   VARIANT     433    433       R -> G (in RNA edited version).
FT                                /FTId=VAR_065019.
FT   VARIANT     441    441       R -> H (functional polymorphism linked
FT                                with susceptibility to major depressive
FT                                disorder; may be due to a rare RNA
FT                                editing event; 80% loss of function;
FT                                decreases solubility; decreases thermal
FT                                stability; reduces catalytic activity;
FT                                dbSNP:rs120074175).
FT                                {ECO:0000269|PubMed:15629698,
FT                                ECO:0000269|PubMed:17905754,
FT                                ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_026749.
FT   VARIANT     468    468       Q -> R (in RNA edited version).
FT                                /FTId=VAR_065020.
FT   VARIANT     479    479       D -> E (moderate loss-of-function
FT                                observed manifested via stability and
FT                                solubility effect; dbSNP:rs7488262).
FT                                {ECO:0000269|PubMed:19319927}.
FT                                /FTId=VAR_058944.
FT   CONFLICT     53     53       S -> N (in Ref. 3; AAI14500).
FT                                {ECO:0000305}.
FT   HELIX       158    161       {ECO:0000244|PDB:4V06}.
FT   HELIX       162    165       {ECO:0000244|PDB:4V06}.
FT   STRAND      168    171       {ECO:0000244|PDB:4V06}.
FT   TURN        180    183       {ECO:0000244|PDB:4V06}.
FT   HELIX       185    199       {ECO:0000244|PDB:4V06}.
FT   HELIX       214    228       {ECO:0000244|PDB:4V06}.
FT   HELIX       231    234       {ECO:0000244|PDB:4V06}.
FT   HELIX       237    249       {ECO:0000244|PDB:4V06}.
FT   HELIX       260    270       {ECO:0000244|PDB:4V06}.
FT   STRAND      274    277       {ECO:0000244|PDB:4V06}.
FT   STRAND      279    282       {ECO:0000244|PDB:4V06}.
FT   HELIX       284    291       {ECO:0000244|PDB:4V06}.
FT   TURN        292    294       {ECO:0000244|PDB:4V06}.
FT   STRAND      295    298       {ECO:0000244|PDB:4V06}.
FT   HELIX       316    322       {ECO:0000244|PDB:4V06}.
FT   HELIX       324    327       {ECO:0000244|PDB:4V06}.
FT   HELIX       330    343       {ECO:0000244|PDB:4V06}.
FT   HELIX       348    359       {ECO:0000244|PDB:4V06}.
FT   TURN        360    364       {ECO:0000244|PDB:4V06}.
FT   STRAND      365    369       {ECO:0000244|PDB:4V06}.
FT   STRAND      372    375       {ECO:0000244|PDB:4V06}.
FT   HELIX       378    382       {ECO:0000244|PDB:4V06}.
FT   HELIX       384    390       {ECO:0000244|PDB:4V06}.
FT   STRAND      392    395       {ECO:0000244|PDB:4V06}.
FT   STRAND      397    399       {ECO:0000244|PDB:4V06}.
FT   HELIX       402    405       {ECO:0000244|PDB:4V06}.
FT   STRAND      412    414       {ECO:0000244|PDB:4V06}.
FT   STRAND      419    423       {ECO:0000244|PDB:4V06}.
FT   HELIX       425    435       {ECO:0000244|PDB:4V06}.
FT   TURN        436    438       {ECO:0000244|PDB:4V06}.
FT   STRAND      442    448       {ECO:0000244|PDB:4V06}.
FT   TURN        449    452       {ECO:0000244|PDB:4V06}.
FT   STRAND      453    457       {ECO:0000244|PDB:4V06}.
FT   HELIX       460    488       {ECO:0000244|PDB:4V06}.
SQ   SEQUENCE   490 AA;  56057 MW;  753645E6E0CE430B CRC64;
     MQPAMMMFSS KYWARRGFSL DSAVPEEHQL LGSSTLNKPN SGKNDDKGNK GSSKREAATE
     SGKTAVVFSL KNEVGGLVKA LRLFQEKRVN MVHIESRKSR RRSSEVEIFV DCECGKTEFN
     ELIQLLKFQT TIVTLNPPEN IWTEEEELED VPWFPRKISE LDKCSHRVLM YGSELDADHP
     GFKDNVYRQR RKYFVDVAMG YKYGQPIPRV EYTEEETKTW GVVFRELSKL YPTHACREYL
     KNFPLLTKYC GYREDNVPQL EDVSMFLKER SGFTVRPVAG YLSPRDFLAG LAYRVFHCTQ
     YIRHGSDPLY TPEPDTCHEL LGHVPLLADP KFAQFSQEIG LASLGASDED VQKLATCYFF
     TIEFGLCKQE GQLRAYGAGL LSSIGELKHA LSDKACVKAF DPKTTCLQEC LITTFQEAYF
     VSESFEEAKE KMRDFAKSIT RPFSVYFNPY TQSIEILKDT RSIENVVQDL RSDLNTVCDA
     LNKMNQYLGI
//
